Are all MRD assays created equal? Understanding ctDNA testing and how it can inform colorectal cancer management

In recognition of Colon Cancer Awareness month, join us as we take a closer look at MRD testing and how this newer technology is being utilized to inform the management in CRC: what are the differences in the various tests and where can they add clarity to patient care? This brief, information-rich webinar with Q&A plans to address how this personalized diagnostic tool is empowering patients and clinicians to make more informed shared decisions along the continuum of care.

What is circulating tumor DNA and how is it used to detect molecular residual disease (MRD) in CRC?
What is meant by a tumor informed assay?
How can these assays be used to detect relapse and why is serial testing so important?

Question Title

* 1. Email

Email Address

Question Title

* 2. Are you a

Clinician

Patient

Caregiver

Question Title

* 3. What questions would you like to submit before our webinar?

Question Title

* 4. Would you like like additional information from Natera?

Yes